What’s Next for CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) After Having More Shares Shorted?

December 23, 2017 - By Marguerite Chambers

Investors sentiment increased to 8 in Q3 2017. Its up 7.00, from 1 in 2017Q2. It improved, as 2 investors sold Cannabis Science, Inc. shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 304,780 shares or 15.15% less from 359,180 shares in 2017Q2 were reported.
Donaldson Capital Limited Liability Com has invested 0% of its portfolio in Cannabis Science, Inc. (OTCMKTS:CBIS). 14,000 are held by Rothschild Corporation Il. The Minnesota-based Stonebridge Capital Advisors Limited Com has invested 0% in Cannabis Science, Inc. (OTCMKTS:CBIS). 20,000 were reported by Frontier. Toth Fincl Advisory Corp, Virginia-based fund reported 11,000 shares. Neville Rodie & Shaw Inc, New York-based fund reported 95,000 shares. Moreover, North Star Asset has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS) for 40,000 shares. Oxbow Limited Liability accumulated 15,000 shares or 0% of the stock.

The stock of CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) registered an increase of 4496.67% in short interest. CBIS’s total short interest was 689,500 shares in December as published by FINRA. Its up 4496.67% from 15,000 shares, reported previously.

The stock increased 11.13% or $0.0065 during the last trading session, reaching $0.0649. About 100.88M shares traded or 553.40% up from the average. Cannabis Science, Inc. (OTCMKTS:CBIS) has 0.00% since December 23, 2016 and is . It has underperformed by 16.70% the S&P500.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $165.61 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

More news for Cannabis Science, Inc. (OTCMKTS:CBIS) were recently published by: Globenewswire.com, which released: “Cannabis Science Expands its Global Research Consortium by Signing …” on December 11, 2017. Globenewswire.com‘s article titled: “Cannabis Science Negotiates for Major Asset Backed Blockchain Crypto Currency …” and published on December 22, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.